rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Innoviva, Inc.

INVA · Nasdaq

Health CarePharmaceuticalsNot moving yet

INVA stood above a rising 150-day average in 30 of the last 52 weekly readings, and has been out of that trend for the last 14 weeks. It is 5.5% below that average now. Pharmaceuticals: 31% of its 74 stocks in an uptrend (−7 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 14
Industry in uptrend
31% -7 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
4
Institutions holding
280 (+25)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 30 of 52 weeks.

17 Apr – 16 Oct
26%36%46%Apr 26Jun 26Jul 26Sep 26Oct 26

Pharmaceuticals: A minority of its stocks are in an uptrend and the share has been slipping. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$27.4M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

4 disclosed lines: House 2, Senate 0, executive 2; 2 people.

WhoDidAmountTraded
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$15k–$50k29 Jul 2026filed 22 Sep 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officebought$15k–$50k30 Jan 2026filed 14 May 2026
George Whitesides House: U.S. House ClerkCA27sold$250k–$500k25 Mar 2025filed 23 Apr 2025
George Whitesides House: U.S. House ClerkCA27sold$50k–$100k24 Mar 2025filed 23 Apr 2025

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders280+25 on the quarter
New · exited48 · 23
Reported value$1.7B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.added · filed 7 Aug 202611,555,209$262.4M+247,364+2.2%
DIMENSIONAL FUND ADVISORS LPadded · filed 11 Aug 20264,494,053$102.1M+57,626+1.3%
VANGUARD PORTFOLIO MANAGEMENT LLCreduced · filed 13 Aug 20264,220,273$95.8M-4,678−0.1%
RENAISSANCE TECHNOLOGIES LLCreduced · filed 13 Aug 20264,036,532$91.7M-19,100−0.5%
STATE STREET CORPadded · filed 7 Aug 20263,268,004$74.2M+207,627+6.8%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20263,158,053$71.7M+16,472+0.5%
MILLENNIUM MANAGEMENT LLCadded · filed 14 Aug 20262,541,109$57.7M+261,658+11.5%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 20262,074,709$47.1M+144,991+7.5%
SYSTEMATIC FINANCIAL MANAGEMENT LPreduced · filed 14 Aug 20262,023,565$46.0M-5170.0%
Boston Partnersadded · filed 4 Aug 20261,927,959$43.8M+209,092+12.2%
31 Mar 2023 – 30 Jun 2026
150213275Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Marianne Zhen Company insiderChief Accounting Officer · last 20 Aug 20260 · 6
Pavel Raifeld Company insiderChief Executive Officer · last 20 Aug 20261 · 0
Stephen Basso Company insiderChief Financial Officer · last 20 Aug 20260 · 0
Donald J. Trump Executive branchWhite House Office · last 29 Jul 20261 · 1
Josephine Linden Company insiderDirector · last 18 May 20260 · 0
Derek A. Small Company insiderDirector · last 4 May 20260 · 0
Jules Haimovitz Company insiderDirector · last 4 May 20260 · 0
Mark DiPaolo Company insiderDirector · last 4 May 20260 · 0
Sarah J. Schlesinger Company insiderDirector · last 4 May 20260 · 0
George Whitesides HouseCA27 · last 25 Mar 20250 · 2
Alexander J. Denner Company insider10% owner · last 6 Mar 20256 · 3
Kostas D. Odysseas Company insiderDirector · last 17 Jun 20240 · 0

Same industry

ABBV AbbVieLeading+20%
VTRS ViatrisLeading+16%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202574.8%
Operating profit marginFY 2025 · to 31 Dec 202539.8%
Free cash flow marginFY 2025 · to 31 Dec 202547.6%
Return on capital employedFY 2025 · to 31 Dec 202510.3%
Debt to equityFY 2025 · to 31 Dec 20250.22×
Interest coverFY 2025 · to 31 Dec 20259.81×
Research spendFY 2025 · to 31 Dec 20257.4%
Share count trendFY 2025 · to 13 Feb 2026-0.8%
Cash and equivalentsFY 2025 · to 31 Dec 2025$550.9M
Free cash flowFY 2025 · to 31 Dec 2025$195.8M

Analyst forecasts

No analyst forecasts yet.